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Abstract: In this paper, two novel liver-targeting nanoparticles, norcantharidin-loaded 
chitosan nanoparticles (NCTD-CS-NPs) and norcantharidin-associated galactosylated chitosan 
nanoparticles (NCTD-GC-NPs), were prepared using ionic cross-linkage. The physical properties, 
particle size, encapsulation efficiency, and drug release characteristics of the nanoparticles were 
investigated in vitro. To investigate the intestinal absorption mechanisms of the two preparations, 
a series of experiments was carried out, including in situ circulation method, in vitro everted gut 
sacs, and Ussing chamber perfusion technique. The absorption rate constants (Ka) of NCTD at 
different segments were found to be duodenum . jejunum . ileum . colon. The concentration 
had no distinctive effect on absorption kinetics, suggesting that drug absorption is not dose-
dependent. The transport of NCTD was found to be inhibited by P-glycoprotein (P-gp) inhibitor, 
indicating that NCTD might be the substrate of P-gp. The order of the absorption enhancer 
effects were as follows: low molecular weight chitosan (CS-8kDa) . high molecular weight 
chitosan (CS-30kDa) . Poloxamer . sodium dodecyl sulfate (SDS) . sodium deoxycholate 
(SDCh). The results indicate that the chitosan nanoparticles can improve intestinal absorption 
of NCTD.
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Introduction
Norcantharidin (NCTD), a demethylation derivative of cantharidin obtained from the 
dried body of the Chinese blister beetle (mylabris), is used as a traditional medicine in 
China.1 Clinical studies have shown that NCTD is effective against the primary carci-
noma of liver as an inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 
2A (PP2A).2 Recent studies have also indicated that NCTD administered orally or 
intravenously has potential applications in cancer chemotherapy.3–7 However, the clini-
cal use of NCTD is limited because of its significant side effects, including irritation 
of the urinary organs.8 Moreover, NCTD usually has to be administered in high doses 
to strengthen its tumor inhibition effects due to its low intestinal permeability. The 
administration of high doses causes more intense irritation at the injection site.
Chitosan (CS), as a nontoxic and biodegradable polycationic polymer with low 
immunogenicity, has been investigated extensively as a formula carrier and delivery 
system for therapeutic molecules, such as gene, protein molecule, vaccine, and 
ammonium glycyrrhizinate.9,10 Among the various mentions of chitosan derivatives 
in literature,11,12 one can differentiate specific reactions involving the free -NH2 
group at the C-2 position. Lactosaminated N-succinylchitosan was found to be a 
good drug carrier in the treatment of liver diseases,13,14 because the lactose base can 
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bind with asialoglycoprotein receptors in the liver surface 
to achieve active liver targeting. To improve the therapeutic 
efficacy of NCTD and decrease its side effects, two novel 
norcantharidin-loaded liver targeting chitosan nanoparticles 
(NCTD-NPs), including norcantharidin-loaded chitosan 
nanoparticles (NCTD-CS-NPs) and norcantharidin-associated 
galactosylated chitosan nanoparticles (NCTD-GC-NPs), were 
successfully developed in our previous studies.15,16 By virtue 
of their unique uptake mechanisms and liver-specific targeting 
properties, NCTD nanoparticles have received much attention 
as a suitable alternative drug carrier system.
Although the physical properties and numerous oral 
dosage forms of NCTD have been studied, the understanding 
of NCTD absorption is very limited. Drug absorption is a 
key process governing in vivo bioavailability of drugs. It is 
affected by the physicochemical properties of the drug, dosage 
form, biological state of the gastrointestinal (GI) tract, and co-
administered food components.17 Various physicochemical 
parameters, such as molecular size and shape, lipophilicity, 
hydrogen bonding capacity, and molecular surface proper-
ties, appear to play crucial roles in the absorption of drugs 
that cross the intestinal barrier through passive diffusion, 
either through the transcellular or paracellular pathway.18–21 
In recent years, several studies have been devoted to the 
assessment of relationships between such parameters and 
drug absorp  tion in various model systems.22–25
In our present study, the absorption mechanisms of 
two nanoparticles of NCTD, NCTD-CS-NPs and NCTD-
GC-NPs, were investigated in comparison with that of 
NCTD. The absorption characteristics of NCTD-NPs in 
the intestinal barrier were studied using in vivo transport 
experiments, in vitro everted sac experiments, and Ussing 
chamber perfusion technique.
Materials and methods
Materials
Norcantharidin (lot number 20100515) with a purity of 
99.21% was purchased from Surui Medicine Chemical Co, 
Ltd (Suzhou, Jiangsu, China). Chitosan with a deacetylation 
of 90.9% and a molecular weight (Mw) from 8 to 30 kDa 
was supplied by Xingcheng Biochemical Co, Ltd (Nantong, 
China). Galactosylated chitosan (GC) was synthesized as 
previously described by Chung et al.26 Sodium tripolyphos-
phate (TPP) was obtained from the National Drug Group 
(Shanghai, China) and Pluronic F68 was purchased from 
Fluka Chemika (Buchs, Switzerland). Other chemicals and 
solvents were of analytical grade. Deionized twice-distilled 
water was used throughout the study.
Male Sprague–Dawley (SD) rats weighing from 220 
to 270 g were obtained from the Laboratory Animals Center 
of the Medical College, Soochow University (Suzhou, China). 
All animal procedures were conducted in accordance with 
the guidelines for the care and use of animals of the National 
Institutes of Health.
Samples preparation
NCTD-NPs were prepared according to a procedure15,16 based 
on the ionic gelation of CS/GC with TPP anions, which was 
slightly modified. Briefly, 200 mg CS/GC was dissolved in 
100 mL acetic acid aqueous solution containing 0.4 mg/mL 
NTCD. TPP aqueous solution was then added to the chito-
san solution drop by drop under magnetic stirring, resulting 
in cross-linkage. After reaction for 10 minutes, 125 mg 
Pluronic F68 was dissolved in the solution as a stabilizer and 
2% acetic acid aqueous solution concentration containing 
chitosan:TPP (50:20 V/V) was stirred at a constant rate of 
500 rpm for 2 hours.
In the method above, NCTD gelata was prepared using 
equivalent distilled water instead of TPP.
The perfusion solution was a Krebs-Ringer buffer 
solution, which contained 7.8 g NaCl, 0.35 g KCl, 1.37 g 
NaHCO3, 0.02 g MgCl2, 0.22 g NaH2PO4, and glucose in 
1.48 g/1000 mL purified water.
Particle size analysis and morphological 
characteristics
Particle size analysis of the NPs was performed by dynamic 
light-scattering measurement using the Zetasizer Nanoparticle 
Analyser (Malvern Instruments Ltd, Malvern, UK) with a 
range from 0.6 to 600 nm. Morphological characteristics of 
the nanoparticles were studied through transmission electron 
microscopy (TEM; JEM-1230, JEOL, Japan). Colloid samples 
of the NPs were condensed using a Vivaflow 50 Ultrafilter 
(30,000 Da polysulfone resin filter membrane; Sartorius AG, 
Göttingen, Germany). A drop of nanoparticle suspension was 
placed onto a carbon film coated on a copper grid for TEM. 
Negative staining was performed using phosphotungstic acid 
(0.05%, w/w). Observation was performed at 80 kV .27
Evaluation of drug entrapment efficiency 
and loading capacity
The concentration of NCTD in the nanoparticles was deter-
mined by a reversed-phase HPLC method. The HPLC system 
was composed of two pumps (LC-10AT VP, Shimadzu, 
Japan) and a UV-vis detector (SPD-M10A VP, Shimadzu) 
set at 210 nm. The chromatographic column was a Luna 
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C18 (4.6 × 250 mm; Hypersil ODS2, Elite, Dalian, China) 
maintained at 30°C. The mobile phase was a mixture of 
acetonitrile: H2O = 10:90 (adjusted to pH 3.1 by adding 
phosphoric acid), and the flow rate was 0.8 mL/min.
An appropriate volume of NPs colloid was filtered 
through a 0.45 μm filter to remove nonsoluble aggregate 
residues following the method in the previous report.28,29 The 
filtered colloid was then ultracentrifuged at 40,000 rpm for 
45 minutes using the Optima MAX Centrifuge (Berkman 
Co, Ltd, USA). The supernatant was sampled and the NCTD 
concentration in the supernatant was determined by HPLC.
Encapsulation efficiency (EE%) and drug loading 
efficiency (DL%) were calculated using the following 
equations:
  EE
TF
T
=
−
× 100% and   (1)
  DL
TF
W
=
-
× 100%   (2)
where T is the total NCTD in the colloid, F is the free 
NCTD in the supernatant, and W is the weight of NPs.
In vitro release studies
Drug release from NCTD- NPs in vitro was measured using a 
dialysis method and compared with that of the NCTD solution. 
Briefly, 6 mL NCTD-NPs was placed into a dialysis tube 
(8000–14,000 MWCO) and sealed at both ends with clips. The 
dialysis tube loaded with nanoparticles was then placed into a 
beaker containing 30 mL deionized twice-distilled water and 
incubated with stirring for 3 hours at 37°C ± 0.5°C. At various 
time points, 0.5 ml aliquots were withdrawn from the beaker 
and replaced with an equal volume of media. The NCTD 
concentrations were then measured by HPLC. The cumulative 
percentage of NCTD released was calculated as the amount of 
NCTD released from the solution or nanoparticles relative to 
the total amount of NCTD present in the formulation.
In vivo transport studies
An in vivo recirculation perfusion technique was used and 
performed as reported previously.30–32 This method was used 
to determine absorption characteristics at four different seg-
ments:33 duodenum, jejunum, ileum, and colon. Three dif-
ferent concentrations were studied: 140 µg/mL, 160 µg/mL, 
and 180 µg/mL. The perfusate was prepared by dispersing 
NCTD/NCTD-NPs with different drug concentrations in 
the Krebs–Ringer BH solution (100 mL) containing phenol 
red (20 µg/mL) for the purpose of correcting the perfusion 
volume. Next, 0.5 mL of the sample solution was used 
to detect the phenol red concentration by UV detection at 
559 nm. Another 0.5 mL was digested by 88% methanoic acid 
(0.33 mL) and then centrifuged for 10 minutes at 4000 rpm. 
Next, 100 µL of the supernatant was separated and placed 
into another centrifuge tube, into which 200 µL methanol 
was added. After vortexing for 3 minutes, the extraction was 
centrifuged for 3 minutes at 10,000 rpm. Afterward, 20 µL 
of the supernatant was injected onto the HPLC for determi-
nation of NCTD using the same HPLC method described 
previously in “Evaluation of drug entrapment efficiency and 
loading capacity.” The absorption percentage (PA), absorption   
rate constant (Ka) and absorption half-life (t  1/2a) for the 
NCTD solution/NCTD-NPs were calculated.
In vitro transport studies
Everted sacs of the rats were prepared using the method 
described previously,34 which was also used to determine 
the absorption characteristics at different segments and with 
different concentrations. All samples were treated using the 
method described in “In vivo transport studies.”
P-gp dependency of NCTD
To examine the saturation potential of the P-gp function, 
the transport of NCTD and NCTD-NPs at the duodenum 
was investigated using the everted sacs method. The P-gp 
inhibitor, Cyclosporin A(CyA), a well-known P-gp substrate, 
was used as the positive control group at concentrations of 
5, 10, and 20 µg/mL.
Effects of absorption enhancers
The effects of improving absorption of NCTD and NCTD-NPs 
used as enhancers at the duodenum were investigated using the 
chamber method. Five enhancers, namely, low molecular weight 
chitosan (CS-8kDa), high molecular weight chitosan (CS-
30kDa), Poloxamer, sodium dodecyl sulfate (SDS), and Sodium 
deoxycholate (SDCh), were used with concentrations of 0.1%, 
0.5%, and 1.0%. Apparent permeability coefficients (Papp) were 
calculated according to the equation below:
  P
dQ
dt AC
app =

 

 
1
0
  (3)
where dQ/dt is the permeability rate, A is the diffusion area, 
and C0 is the initial donor solution concentration.
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Statistics
Values are expressed as  x ± s (mean ± SD). Data were 
analyzed by one-way ANOVA with the post-hoc Tukey’s 
test applied for paired comparisons (SPSS 16, SPSS Inc, 
Chicago, USA). Moreover, the criterion of statistical signifi-
cance was taken as *P , 0.05, **P , 0.01, or #P , 0.05, 
##P , 0.01.
Results and discussion
Physicochemical properties  
of NCTD-NPs
The physicochemical characteristics of NCTD-NPs, includ-
ing particle size and yield, drug loading, and encapsulation 
efficiency, are summarized in Table 1. The two liver-
targeting NCTD-loaded nanoparticles, NCTD-CS-NPs and 
NCTD-GC-NPs, had small particle sizes of about 100 nm 
and displayed an encapsulation efficiency of about 50%, 
leading to the final NCTD loading values of about 10%. The 
values of the NCTD-GC-NPs were higher than those of the 
NCTD-CS-NPs.
The majority of the fenestrate of the liver sinusoid was 
reported to be typically less than 200 nm in diameter.35 
Permeability of the vascellum endothelium existing in the 
liver tumor was also enhanced greatly.36 Thus, the novel 
NCTD-CS-NPs could pass through the fenestrate sinusoid 
and accumulate in the tumor sites of the liver. The small 
particle size could reduce the adverse reaction of NCTD-NPs 
on normal hepatic cells and reduce passive liver-targeting. 
The two NCTD-NPs appeared spherical in shape, as shown 
in Figure 1.
In vitro drug release of NCTD-NPs
The data results of in vitro NCTD release characteristics are 
presented in Figure 2. The release curve conforms to the 
Table 1 Physicochemical characteristics of NCTD nanoparticles (n = 3)
NCTD 
nanoparticles
Mean particle size  
(nm)
Encapsulation efficiency  
(%)
Drug loading efficiency  
(%)
Yield 
(%)
NCTD-CS-NPs 131 ± 11 45.12 ± 0.33   7.3 ± 0.13 99.62 ± 0.15
NCTD-GC-NPs 119 ± 9 57.92 ± 0.40 10.38 ± 0.06 98.71 ± 0.22
Abbreviations:  NCTD-CS-NPs  nanoparticles,  norcantharidin-loaded  chitosan  nanoparticles;  NCTD-GC-NPs,  norcantharidin-associated  galactosylated  chitosan 
nanoparticles.
100 nm 100 nm
×50000 ×50000
AB
Figure 1 TEM photograph of NCTD-CS-NPs (A) and NCTD-GC-NPs (B).
Abbreviations:  NCTD-CS-NPs  nanoparticles,  norcantharidin-loaded  chitosan  nanoparticles;  NCTD-GC-NPs,  norcantharidin-associated  galactosylated  chitosan 
nanoparticles; TEM, transmission electron microscope.
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Weibull model; the soluble equation is plotted using the data 
and a good fit is achieved. Td, T50 and other parameters are 
calculated according to the soluble equation; the results are 
shown in Table 2. Analysis of the data shows that Td, T50 of 
the two formulations are significantly different (P , 0.01) and 
the parameters of NCTD-NPs are significantly less than the 
gelata, which means that NCTD-NPs are more conducive for 
the release of the drugs than the gelata.37 In conclusion, the in 
vitro release of nanoparticles was found to follow the Weibull 
equation (data not shown) by data fitting (r . 0.9500). The 
drug release of NCTD-NPs was more complete than that of 
NCTD gelata. It was also argued that NCTD-NPs were more 
conducive to drug delivery than NCTD gelata.38
Absorption properties  
of NCTD-NPs in rat intestines
Absorption of NCTD-NPs  
in various intestinal segments of rats
Regional differences in intestinal drug permeability have 
been attributed to the difference in epithelial surface area, 
pore radius of the paracellular pathway, mucus layer, and 
regional membrane fluidity.39 In this NCTD-NPs study, the 
absorption tests were performed on four different intesti-
nal segments to test whether the intestinal absorption of 
NCTD-NPs exhibited site-dependent changes. The intestinal 
absorption kinetics of NCTD-NPs and NCTD solution at a 
dose of 160 µg/mL were investigated. The results are shown 
in Table 3, from which it could be concluded that NCTD 
absorption through the duodenum and the jejunum were 
much higher than those through the ileum and colon. The Ka 
of NCTD absorption was duodenum . jejunum . ileum . 
colon. In addition, drug absorption is affected mainly by the 
physicochemical properties of drugs, drug metabolism in the 
gastrointestinal mucosa, lipophilicity, unionized fraction of 
drugs, molecular size, and drug solubility.40 Changing these 
absorption parameters along the gastrointestinal tract may 
contribute to the differences in site-specific absorption of 
melatonin. Regional differences in the functional expression 
of P-gp might be one of the possible factors for site-dependent 
absorption. Compared to the in vitro everted sac method, 
Ka of the in vivo method was much higher while t1/2a was 
much lower. This is because during the in vitro method, the 
mesentery and blood vessels were cut off, which leads to less 
absorption. Among the three formulations, the order of Ka 
was NCTD-GC-NPs . NCTD-CS-NPs . NCTD solution. 
It has been suggested that chitosan nanoparticles could 
improve the intestinal absorption of NCTD because chitosan 
can trigger the opening of tight junctions.41 In addition, there 
are plenty of Peyer’s patches and M cells in rat intestines, 
and absorption via the lymphatic tissues is an important route 
for drugs with low oral bioavailability.42–44 Nanoparticles, 
as compositions of intestine mucous membrane, have an 
important effect on the enhancement of absorption via the 
lymphatic route.45
Absorption of NCTD-NPs in various 
concentrations in rats
As shown in Figure 3, the intestinal absorption percentages 
of NCTD at higher concentration were greater than those 
at lower concentrations in vivo or in vitro. However, the 
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Figure 2 In vitro drug release of NCTD-CS-NPs (◊) and NCTD-GC-NPs (▲) 
compared with NCTD gelata (●).
Abbreviations:  NCTD-CS-NPs  nanoparticles,  norcantharidin-loaded  chitosan 
nanoparticles;  NCTD-GC-NPs,  norcantharidin-associated  galactosylated  chitosan 
nanoparticles.
Table 2 Soluble equation and parameters (n = 5)
Group Weibull equation r Td/min T50/min
NCTD-CS-NPs InIn[1/1-F(t)] = 0.532Int-1.3334 0.97379 12.25 ± 0.3   6.15 ± 0.2
NCTD-GC-NPs InIn[1/1-F(t)] = 0.3775Int-0.9438 0.95917 12.17 ± 0.5   4.61 ± 0.3
NCTD gelata InIn[1/1-F(t)] = 0.370Int-1.6412 0.97528 84.33 ± 0.7 31.35 ± 0.6
Abbreviations:  NCTD-CS-NPs  nanoparticles,  norcantharidin-loaded  chitosan  nanoparticles;  NCTD-GC-NPs,  norcantharidin-associated  galactosylated  chitosan 
nanoparticles.
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different concentrations did not induce a difference in the 
transport of NCTD (P . 0.05). It has been suggested that the 
concentration has no distinctive effect on absorption kinetics. 
A comparison of absorption kinetics among different con-
centrations demonstrated a non-concentration-dependent 
change. Results indicated that the intestinal absorption of 
NCTD-NPs is via passive transfer by diffusion across the 
intestinal membranes.46
P-gp dependency of NCTD
P-glycoprotein efflux pumps are located predominantly 
in the apical membranes of the epithelia (eg, small 
intestine, colon) and significantly limit oral absorption of a 
number of drugs.47
The transport of NCTD across everted gut sacs in 
solutions with added 5, 10, and 20 µg/mL CyA is shown 
in Figure 4. Results showed that the NCTD cumulative 
percentage in the duodenum at 120 minutes was signifi-
cantly enhanced by CyA (P , 0.05). As the CyA concen-
tration increased, the cumulative concentration of NCTD 
gradually increased. When the concentration of CyA 
was 20 µg/mL, the accumulative concentration of NCTD 
at 120 min was more than 200% of the control (in the 
absence of CyA).
Table 3 Absorption parameters at various segments in rat intestines (n = 3)
Segment Groups PA/% Ka/h-1 × 100 t1/2a/h
In vivo (6 hours) In vitro (2 hours) In vivo In vitro In vivo In vitro
Duodenum NCTD solution 15.69 ± 1.12   4.76 ± 0.22 3.06 ± 0.33 2.81 ± 0.21 22.67 ± 2.44 24.70 ± 1.85
NCTD-CS-NPs 29.16 ± 1.87 13.21 ± 1.13 6.89 ± 0.21 5.98 ± 0.37 10.06 ± 0.31 11.59 ± 0.72
NCTD-GC-NPs 35.79 ± 0.34 16.48 ± 075 6.97 ± 0.42 9.05 ± 0.51   9.95 ± 0.15   7.66 ± 0.37
Jejunum NCTD solution 12.49 ± 0.89   4.70 ± 0.15 2.78 ± 0.26 2.60 ± 0.13 24.93 ± 2.33 26.61 ± 1.33
NCTD-CS-NPs 24.34 ± 1.01 10.88 ± 0.34 5.92 ± 0.35 4.24 ± 0.23 11.71 ± 0.69 16.36 ± 0.89
NCTD-GC-NPs 29.43 ± 0.15 16.65 ± 1.21 6.16 ± 0.52 9.10 ± 0.36 11.25 ± 0.51   7.62 ± 0.53
Ileum NCTD solution   7.73 ± 0.25   2.76 ± 0.12 1.51 ± 0.14 1.54 ± 0.17 45.89 ± 4.25 44.90 ± 4.96
NCTD-CS-NPs 13.98 ± 0.97   8.20 ± 0.27 3.53 ± 0.17 2.76 ± 0.07 19.63 ± 0.95 25.13 ± 0.64
NCTD-GC-NPs 17.67 ± 0.27   8.32 ± 0.13 4.09 ± 0.25 4.08 ± 0.11 16.94 ± 0.77 17.00 ± 0.75
Colon NCTD solution   2.20 ± 0.33   1.18 ± 0.08 0.44 ± 0.01 0.71 ± 0.02 157.5 ± 3.58 97.54 ± 2.75
NCTD-CS-NPs   3.54 ± 1.23   2.28 ± 0.06 0.95 ± 0.01 0.80 ± 0.01 72.95 ± 0.78 86.59 ± 1.08
NCTD-GC-NPs   9.59 ± 0.23   3.61 ± 0.03 1.36 ± 0.23 1.74 ± 0.15 50.90 ± 1.23 39.73 ± 2.41
Abbreviations:  NCTD-CS-NPs  nanoparticles,  norcantharidin-loaded  chitosan  nanoparticles;  NCTD-GC-NPs,  norcantharidin-associated  galactosylated  chitosan 
nanoparticles.
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Figure 3 Intestinal absorption of NCTD-CS-NPs (×) and NCTD-GC-NPs (◊) compared with that of NCTD solution (▲) at different concentrations in vivo (A) and in vitro (B).
Abbreviations: NCTD-CS-NPs nanoparticles, norcantharidin-loaded chitosan nanoparticles; NCTD-GC-NPs, norcantharidin-associated galactosylated chitosan nanoparticles.
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Figure 4 Intestinal absorption in vitro of NCTD with different concentrations of CyA.
Note: *P , 0.05 versus 5 µg/mL group.
Abbreviations:  NCTD-CS-NPs  nanoparticles,  norcantharidin-loaded  chitosan  nanoparticles;  NCTD-GC-NPs,  norcantharidin-associated  galactosylated  chitosan 
nanoparticles.
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Figure 5 Effects of absorption enhancers on the apparent permeability coefficients (Papp) for different concentrations.
Notes: *P , 0.05 versus no enhancer group; **P , 0.01 versus no enhancer group.
Abbreviations: CS, chitosan; Papp, permeability coefficients; SDCh, sodium deoxycholate; SDS, sodium dodecyl sulfate.
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Effects of absorption enhancers
The results are shown in Figure 5. Compared with the NCTD 
solution, absorption enhancers can enhance the absorption rate 
of the drug. The order of cross-mucosal permeability is CS-8-
KDa . CS-30KDa . Poloxamer . SDS . SDCh. Among 
them, 0.1% CS-8KDa showed the most significant absorption 
promotion effect. With different concentrations of absorption 
enhancers to promote absorption between the different degrees, 
SDCh and Poloxamer absorption increased as the concentration 
was increased. SDS as an anionic surfactant promotes the role 
of low concentration; upon reaching a certain concentration, 
its effect decreased. The effect of CS-8KDa on absorption 
decreased as the concentration was increased. Thus it is proven 
that drugs containing low molecular weight chitosan as a carrier 
can help to promote intestinal absorption. The reason may be 
as follows: on the one hand, chitosan has a biological adhesive 
function, which can extend drug residence time in the intestines; 
on the other hand, because of its positively charged nature, it 
can connect with a variety of negatively charged protein bind-
ings in the intestinal mucosa effectively, thereby inhibiting the 
physiological functions of certain proteins.48
Conclusion
Three intestinal absorption models in vivo and in vitro were 
used. They are simple, easy, and effective for drug absorption 
studies. The intestinal absorption mechanisms of NCTD solu-
tion and NCTD-NPs were investigated. Results of the study 
showed that NCTD-NPs significantly enhance drug absorp-
tion compared with the NCTD solution. Intestinal absorption 
kinetics provides methods for a more profound study of the 
process in vivo and in the development of new oral drugs.
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